Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KROS 
Keros Therapeutics Inc (KROS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KROS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $29.2
1 Year Target Price $29.2
| 5 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.95% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 547.90M USD | Price to earnings Ratio - | 1Y Target Price 29.2 |
Price to earnings Ratio - | 1Y Target Price 29.2 | ||
Volume (30-day avg) 13 | Beta 1.29 | 52 Weeks Range 9.12 - 72.37 | Updated Date 06/30/2025 |
52 Weeks Range 9.12 - 72.37 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.96% | Operating Margin (TTM) 71.97% |
Management Effectiveness
Return on Assets (TTM) -1.01% | Return on Equity (TTM) 0.71% |
Valuation
Trailing PE - | Forward PE 49.02 | Enterprise Value -154226066 | Price to Sales(TTM) 2.55 |
Enterprise Value -154226066 | Price to Sales(TTM) 2.55 | ||
Enterprise Value to Revenue 6490.26 | Enterprise Value to EBITDA -13.05 | Shares Outstanding 40615400 | Shares Floating 28132673 |
Shares Outstanding 40615400 | Shares Floating 28132673 | ||
Percent Insiders 2.31 | Percent Institutions 110.36 |
Analyst Ratings
Rating 4 | Target Price 29.2 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Keros Therapeutics Inc
Company Overview
History and Background
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of hematological and pulmonary disorders. Founded in 2017, they have rapidly advanced several programs into clinical trials.
Core Business Areas
- Hematology: Development of therapeutics for hematological disorders, including anemia and thrombocytopenia.
- Pulmonary Diseases: Development of therapeutics for pulmonary disorders, such as pulmonary arterial hypertension (PAH).
Leadership and Structure
The leadership team consists of Kleanthis G. Xanthopoulos, Ph.D. (President and CEO), and other experienced biotech executives. The organizational structure is typical of a clinical-stage biotech company, focusing on research and development, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- KER-050: An activin receptor-like kinase 1 (ALK1) ligand trap being developed for the treatment of myelodysplastic syndromes (MDS) and myelofibrosis-associated anemia. Market share data is not yet available as it is in clinical trials. Competitors in the anemia space include Acceleron Pharma (acquired by Merck) and Bristol Myers Squibb (REBLOZYL).
- KER-047: An activin receptor type IIA (ActRIIA) ligand trap being developed for the treatment of pulmonary arterial hypertension (PAH). Market share data is not yet available as it is in clinical trials. Competitors in the PAH space include Johnson & Johnson and United Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies for unmet medical needs. The hematology and pulmonary disease markets are large and growing, driven by aging populations and increasing prevalence of chronic diseases.
Positioning
Keros Therapeutics is positioned as an innovator in the hematology and pulmonary disease space, focusing on novel ligand trap technology. Their competitive advantage lies in their differentiated approach to targeting key signaling pathways involved in disease pathogenesis.
Total Addressable Market (TAM)
The TAM for MDS, myelofibrosis-associated anemia, and PAH is estimated to be billions of dollars annually. Keros is positioned to capture a significant share of this market if their clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Novel ligand trap technology
- Strong intellectual property portfolio
- Experienced management team
- Promising clinical trial results
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapies
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Favorable regulatory environment
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- BMS (BMY)
- MRK (MRK)
- UTHR (UTHR)
- JNJ (JNJ)
Competitive Landscape
Keros Therapeutics competes with established pharmaceutical companies with larger resources and existing therapies. However, Keros' novel approach to targeting key signaling pathways provides a potential competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of its pipeline through preclinical and clinical development.
Future Projections: Future growth is dependent on the success of ongoing clinical trials and potential regulatory approvals. Analyst estimates vary depending on the perceived probability of success of their pipeline.
Recent Initiatives: Recent initiatives include the advancement of KER-050 and KER-047 into later-stage clinical trials and presentations at major scientific conferences.
Summary
Keros Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of novel therapeutics. Their ligand trap technology and focus on hematological and pulmonary disorders offer significant potential. Success hinges on positive clinical trial results and securing partnerships. Competition from larger players and the inherent risks of drug development present significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Keros Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Keros Therapeutics Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2020-04-08 | CEO & Chair of the Board Dr. Jasbir S. Seehra Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.kerostx.com |
Full time employees 163 | Website https://www.kerostx.com | ||
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.